Acifran
Acifran is a pharmaceutical compound that has been studied for its potential effects on lipid metabolism and cholesterol levels. It is classified as a hypolipidemic agent, which means it is used to lower lipid levels in the blood.
Mechanism of Action[edit | edit source]
Acifran works by activating the peroxisome proliferator-activated receptor (PPAR), specifically the PPAR-alpha subtype. This activation leads to an increase in the oxidation of fatty acids and a reduction in the synthesis of triglycerides. As a result, it helps in lowering the levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood, while potentially increasing the levels of high-density lipoprotein (HDL) cholesterol.
Clinical Uses[edit | edit source]
While Acifran has shown promise in preclinical studies, its clinical use is not well-established. It has been primarily investigated for its potential to treat conditions such as hyperlipidemia and atherosclerosis. However, more research is needed to fully understand its efficacy and safety profile.
Side Effects[edit | edit source]
The side effects of Acifran are not well-documented due to the limited clinical data available. However, as with other hypolipidemic agents, potential side effects could include gastrointestinal disturbances, liver enzyme abnormalities, and muscle pain.
Related Compounds[edit | edit source]
Acifran is related to other PPAR agonists, such as fibrates and thiazolidinediones. These compounds also target lipid metabolism and are used in the treatment of various metabolic disorders.
Research and Development[edit | edit source]
Ongoing research is focused on understanding the full therapeutic potential of Acifran, including its long-term effects and safety. Studies are also being conducted to explore its use in combination with other lipid-lowering agents.
See Also[edit | edit source]
- Hypolipidemic agent
- Peroxisome proliferator-activated receptor
- Hyperlipidemia
- Atherosclerosis
- Fibrates
- Thiazolidinediones
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
